Clinical Trial Protocol Registry

Trial information

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Status:
Active, not recruiting
Protocol number:
ML25288
Sponsor:
Hoffmann-La Roche
Company division:
Pharmaceutical
Product name:
Herceptin
Generic name:
TRASTUZUMAB EMTANSINE
Official Scientific Title:
A Multicenter, Single arm, Open-Label PhIV study to investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (neo)adjuvant Herceptin for HER2-Positive Early Breast Cancer
Brief summary:
This single arm, open-label study will evaluate the efficacy and safety of Herceptin (trastutumab) in combination with a taxane as first line therapy in patients with HER2-positive breast cancer who relapsed after neoadjuvant or adjuvant Herceptin treatment. Patients will receive Herceptin (loading dose of 4 mg/kg intravenously [iv], 2 mg/kg iv weekly thereafter) with 6 3-week cycles of either docetaxel (100 mg/m2 iv every 3 weeks) or paclitaxel (90 mg/m2 every week). Herceptin treatment will be continued until disease progression or unacceptable toxicity occurs. Target sample size is 32.
Study phase:
IV
Study type:
Interventional; Treatment; Non-randomized; Open label; Single group; Safety/efficacy study
Conditions:
  • Breast Cancer
Primary outcome:
  1. Progression-free survival, tumour assessments according to RECIST criteria Time frame: up to 4 years
Key secondary outcomes:
  1. Overall response rate (Complete and partial response), tumour assessments according RECIST criteria Time frame: up to 4 years
  2. Duration of response: Time from objective response to disease progression Time frame: up to 4 years
  3. Overall survival Time frame: up to 4 years
  4. Safety: Incidence of adverse events Time frame: up to 4 years
  5. Determination of biomarkers indicative for response (serum and tumour tissue analyses) Time frame: up to 4 years
Inclusion criteria:
  • Female patients, >/= 18 years of age
  • Locally recurrent/metastatic breast cancer (relapse in supra- or infraclavicular lymph nodes is regarded as metastatic disease)
  • HER2-positive primary disease
  • Patients must have received Herceptin in the adjuvant and/or neoadjuvant setting
  • Relapsed breast cancer >/= 6 months after discontinuing last drugs of Herceptin and/or chemotherapy in the adjuvant and/or neoadjuvant setting for HER2-positive breast cancer
  • Measurable disease according to RECIST 1.0
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Maximum cumulative dose of doxorubicin </= 360 mg/m2 or of epirubicin </= 720 mg/m2 or no prior anthracyclines
  • At least 3 weeks after prior surgery or radiotherapy
Exclusion criteria:
  • Pregnant or breastfeeding women
  • Previous chemotherapy for metastatic breast cancer (prior endocrine therapy till progressive disease is allowed)
  • Pleural effusions, ascites or bone lesions as only manifestation of disease
  • Brain metastases
  • Invasive malignancy other than metastatic breast cancer
  • Inadequate bone marrow, hepatic or renal function
  • Prior treatment with anti-HER therapies other than (neo)adjuvant Herceptin
Gender:
Females
Age limits:
Min: 18 years Max: N/A (No limit)
Accepts healthy volunteers:
No
Anticipated start date:
March, 2011
Trial registration date:
02.02.2011
Date last updated:
07.04.2014
This trial was conducted at the following locations:
China
  • BEIJING
  • GUANGZHOU
  • HANGZHOU
  • JIANGSU
  • SHANGHAI
  • WUHAN
CHINA
  • Beijing
  • Chengdu
  • GUANGDONG PROVINCE
  • Guangzhou
  • HANGZHOU
  • Harbin
  • Shenyang
  • Wuhan
  • Zhengzhou

Link to trial result

For more information on a specific Roche trials in your country location, please contact your local Roche affiliate nearest you.

  • Go on the URL link- http://www.roche.com and click on the Roche Worldwide tab on the top of the page to locate the country nearest you for contact information.

Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the global studies, please have your healthcare provider contact us and they will be provided with the relevant clinical trial information.

For US or global trials with US sites only, please contact the Trial Information Support Line (TISL)